Clinical trials: Cabozantinib
Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been treated with cabozantinib, and…
- Conditions
- Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Carcinoid Tumor
- Trial name
- NCT05263050
- Testing
- Cabozantinib, Nivolumab
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Fox Chase Cancer Center
Healthy, Hepatic Impairment
Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects
The main objective of this study is to compare the pharmacokinetics (PK) of a single oral 75 mg dose of cabozantinib in hepatic impaired adult subjects to healthy adult subjects.
- Trial name
- NCT01493869
- Testing
- cabozantinib
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Exelixis
Hepatocellular Carcinoma Non-resectable
A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab
Hepatocellular carcinoma (HCC) is the most common liver cancer and a leading cancer death worldwide. Currently, atezolizumab and bevacizumab combination is the standard of care for patients with advanced HCC.
- Trial name
- CPAB (NCT06535737)
- Testing
- Cabozantinib
- Volunteers
- 40 people
- Sponsor
- Chulalongkorn University
Hepatocellular Carcinoma
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic effect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular…
- Trial name
- ZENOBIA (NCT06698250)
- Testing
- Zanzalintinib, Durvalumab, Tremelimumab
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Anwaar Saeed
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
This pilot clinical trial studies cabozantinib-s-malate in treating patients with hormone-resistant metastatic prostate cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for…
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01812668
- Testing
- cabozantinib-s-malate, fluorine F 18 d-FMAU, positron emission tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Medullary Thyroid Cancer
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
A study to evaluate the efficacy and safety of pralsetinib compared with SOC treatment (cabozantinib or vandetanib) for participants with RET (rearranged during transfection)-mutant MTC who have not previously received a SOC…
- Trial name
- AcceleRET-MTC (NCT04760288)
- Testing
- Pralsetinib, Cabozantinib, Vandetanib
- Where
- Spain
- Sponsor
- Hoffmann-La Roche
Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
This phase I/Ib trial seeks to find out the best dose, possible benefits and/or side effects of cabozantinib in combination with enfortumab vedotin in treating urothelial cancer that has spread to nearby tissues and lymph nodes…
- Conditions
- Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
- Trial name
- NCT04878029
- Testing
- Cabozantinib S-malate, Enfortumab Vedotin, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Emory University
Locally Advanced Osteosarcoma, Metastatic Osteosarcoma
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
This phase II trial studies the effect of atezolizumab and cabozantinib in treating adolescents and young adults with osteosarcoma that has come back (recurrent) or has spread to other places in the body (metastatic).
- Conditions
- Locally Advanced Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma
- Trial name
- NCT05019703
- Testing
- Atezolizumab, Cabozantinib
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Nephrotoxicity
Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.
This is a prospective, single-arm, single-center, exploratory study. The purpose of this study is to explore the effect of Huaier Granule on nephrotoxicity associated with anti-angiogenesis targeted therapy for advanced…
- Trial name
- NCT05673824
- Testing
- Huaier Granule, VEGFR-TKIs
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Fudan University
Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
This phase I trial evaluates the effects of CBM588 in combination with standard therapies, nivolumab and cabozantinib, in treating patients with kidney cancer that has spread to other places in the body (advanced/metastatic).
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma
- Trial name
- NCT05122546
- Testing
- Cabozantinib S-malate, Clostridium butyricum CBM 588 Probiotic Strain, Nivolumab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Carcinoma, Renal Cell
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally…
- Trial name
- CONTACT-03 (NCT04338269)
- Testing
- Atezolizumab, Cabozantinib
- Where
- 135 sites in United States, Argentina and 13 more
- Volunteers
- 522 people
- Sponsor
- Hoffmann-La Roche
Renal Cell Carcinoma
Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.
The purpose of the protocol is to assess the Overall Survival (OS) at 1 year in patients after cabozantinib initiation.
- Trial name
- CAROLINE (NCT04609800)
- Sponsor
- Ipsen
Renal Cell Carcinoma
Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England
The present study will aim to describe and understand, in the real-world, the clinical characteristics, treatment patterns and outcomes of advanced renal cell carcinoma (aRCC) patients treated with cabozantinib or axitinib…
- Trial name
- NCT04637204
- Testing
- Cabozantinib, Axitinib
- Where
- United Kingdom
- Volunteers
- 1,540 people
- Sponsor
- Ipsen
Osteosarcoma, Pediatric Osteosarcoma
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
This clinical study is the initiative of the FOSTER (Fight OsteoSarcoma Through European Research) consortium and Gustave Roussy, which is the sponsor.
- Conditions
- Osteosarcoma, Pediatric Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
- Trial name
- FOSTER (NCT07871864)
- Testing
- Experimental group : Cabometyx ® 40mg/m2/day (Max: 60mg/day) , Treatment schedule : Daily**, day 1-28 during 4 weeks (ie. 1 cycle) during 12 cycles
- Where
- 77 sites in Denmark, Finland and 6 more
- Volunteers
- 530 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Kidney Cancer, Renal Cell Carcinoma
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
The purpose of this study is to determine if the use of immunotherapy nivolumab and the targeted therapy cabozantinib prior to removal of the kidney, will increase the number subjects who are without any visible kidney cancer in…
- Trial name
- Cyto-KIK (NCT04322955)
- Testing
- Cabozantinib, Nivolumab, Cytoreductive nephrectomy
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Mark Stein
Healthy, Renal Impairment
A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function
The main objective of the trial is to compare the pharmacokinetics of a 60 mg dose of cabozantinib in adult subjects with impaired renal function compared with healthy adult subjects.
- Trial name
- NCT01761773
- Testing
- cabozantinib
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Exelixis
Metastatic Castration-resistant Prostate Cancer
Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
This is an open-label, phase 1b dose-escalation study of cabozantinib in combination with 177Lu-PSMA-617 in subjects with mCRPC.
- Trial name
- CaboLu (NCT05613894)
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Utah
Thyroid Cancer
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
The purpose of this research study is to evaluate the progression-free survival (PFS) with XL184 as compared with placebo (an inactive substance) in subjects with unresectable, locally advanced, or metastatic medullary thyroid…
- Trial name
- EXAM (NCT00704730)
- Testing
- XL184
- Where
- 113 sites in United States, Austria and 22 more
- Volunteers
- 330 people
- Sponsor
- Exelixis
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
This phase I/II trial studies the side effects and best dose of sapanisertib when given together with cabozantinib, and to see how well they work in treating patients with liver cancer that has spread from where it first started…
- Conditions
- Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT06811116
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Imaging Procedure
- Where
- 4 sites in United States
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
This phase II trial compares the effect of immunotherapy with ipilimumab and nivolumab alone to their combination with cabozantinib in treating patients with soft tissue sarcoma that has spread from where it first started to…
- Conditions
- Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma
- Trial name
- NCT05836571
- Testing
- Biopsy Procedure, Biospecimen Collection, Cabozantinib
- Where
- 27 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute LAO